MASLD and MASH: Clinical Spectrum and Modern Management, An Issue of Clinics in Liver Disease
Series: The Clinics: Internal Medicine;
- Publisher's listprice EUR 91.99
-
35 931 Ft (34 220 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 13% (cc. 4 671 Ft off)
- Discounted price 31 260 Ft (29 771 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
35 931 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Health Sciences
- Date of Publication 20 May 2026
- ISBN 9780443413537
- Binding Hardback
- No. of pages pages
- Weight 450 g
- Language English 697
Categories
Long description:
In this issue of Clinics in Liver Disease, guest editor Dr. Zobair M. Younossi brings his considerable expertise to the topic of MASH/NASH Fatty Liver. With an estimated 115 million people worldwide affected by MASH, the disease burden casts a wide net: many have other comorbidities, like diabetes, that make diagnosis and treatment critical. MASH-related liver cancer has increased 20% since 1990, and MASH is becoming a leading cause of liver transplants in adults, reflecting its significant impact on liver health. This issue provides state-of-the-art clinical reviews on MASH and NASH and also shines a light on the disease burden across the globe.
- Contains 19 relevant, practice-oriented topics including association of MASH with metabolic-related diseases (diabetes, pre-diabetes, and obesity); algorithms for risk stratification in patients with MASH; management of MASLD: lifestyle modification; currently approved and future regimens for MASH; pediatric MASH; and more
- Provides in-depth clinical reviews on MASH/NASH fatty liver, offering actionable insights for clinical practice
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews
Table of Contents:
Metabolic Dysfunction-Associated Steatotic Liver Disease: Global Epidemiology, Patient-Reported Outcomes, and Economic Impact
Association of Metabolic Dysfunction-Associated Steatohepatitis with Metabolic- Related Diseases: Diabetes, Prediabetes, and Obesity
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease with Extrahepatic Cancers and Sarcopenia
Metabolic Liver Disease Beyond the Liver: Association of Metabolic Dysfunction- Associated Steatotic Liver Disease with Cardiovascular and Renal Diseases
Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Algorithms for Risk Stratification in Patients with Metabolic Dysfunction- Associated Steatohepatitis
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease with Lifestyle Modification
Treatment of Modifiable Risks in Metabolic Dysfunction-Associated Steatotic Liver Disease: Drugs Targeting Obesity and Type 2 Diabetes
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Special Populations: Hepatocellular Carcinoma Risk and Liver Transplantation
Special Population: Lean MASH
Special Population: A Global Perspective on Metabolic Dysfunction-Associated Alcohol-Related Liver Disease
What’s New in Pediatric Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap
Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management
Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action
Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America
Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean
Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis
